Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapiesdoi:10.1038/s41408-023-00945-0STEM cell transplantationAMYLOIDOSISPROGRESSION-free survivalOVERALL survivalThis letter published in the Blood Cancer Journal pr...
Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being...
Immunoglobulin light chainamyloidosis(AL) is a cancer of plasma cells that secrete unstable full-lengthimmunoglobulinlight chains. These light chains misfold and aggregate, often with aberrant endoproteolysis, leading toorgan toxicity.ALis currently treated by pharmacological elimination of the cl...
Light-chain (AL) amyloidosisCardiac amyloidosisHeart failureNT-proBNPFree light-chainsDexamethasoneTreatmentMortality mortalityChemotherapy combining cyclophosphamide, bortezomiband dexamethasone is widely used in light-chain amyloidosis. The benefit is limited in patients with cardiac amyloidosis mainly because of...
Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. ...
Amyloidosisperiureteralretroperitonealsoft tissuenephrostomyRetroperitoneal involvement is rare in patients with light chain (AL) amyloidosis and has only been published as case reports. Only 5 cases of retroperitoneal deposition have previously been reported in the setting of systemic AL amyloidosis. Data ...
Palladini G, Schonland SO, Sanchorawala, et al. Clarification on the definition of complete haematologic response in light- chain (AL) amyloidosis. Amyloid 2021 Mar;28:1-2. ABBR-1 • New section added: Abbreviations Version 2.2023, 11/28/22 © 2022 National Comprehensive Cancer Network®...
Immunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition. The cytogenetic pattern of AL shows profound similarity with that of other pl
et al.Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.J Cancer Res Clin Oncol148, 913–919 (2022). https://doi.org/10.1007/s00432-021-03653-z DOIhttps://doi.org/10.1007/s00432-021-03653-z ...
Two types of amyloid protein cause more than 95% of cardiac amyloidosis: immunoglobulin light chain, which causes light chain amyloidosis (AL), and transthyretin, which causes hereditary or wild-type (previously called senile systemic amyloidosis) transthyretin amyloidosis (ATTR). Although hereditary ...